- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01859884
Optimizing Kidney Transplant Informed Consent
November 18, 2015 updated by: Elisa Gordon, Northwestern University
Optimizing Kidney Transplant Patients' Informed Consent for Increased Risk Donors
The objective of this study is to evaluate kidney transplant candidates' comprehension about increased risk donor kidneys necessary for informed consent.
We have developed a web-based tool that educates and assesses candidates' comprehension (Inform Me), as a supplement to current informed consent processes.
We will then compare the effectiveness of the current informed consent processes supplemented by Inform Me, with the current consent processes alone for kidney transplant.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The shortage of kidneys for kidney transplantation results in almost 10,000 deaths per year in the United States.
One strategy to increase the number of available kidneys is to offer kidney transplant candidates kidneys that come from donors who have an increased risk of transmission of human immunodeficiency virus (HIV), Hepatitis B and Hepatitis C. Increased risk kidney donors are defined as those who have engaged in behaviors associated with an increased risk of HIV, Hepatitis B, and Hepatitis C, and comprise approximately 9% of all US deceased organ donors.
The Organ Procurement and Transplantation Network policy mandated informed consent from recipients who accept increased risk kidneys.
The objective of this study is to increase study participants' comprehension about increased risk donor kidneys necessary for informed consent.
To accomplish this objective, we will develop a web-based tool that educates and assesses participants' comprehension (Inform Me), as a supplement to current informed consent processes.
We will then compare the effectiveness of the current informed consent processes supplemented by Inform Me, with the current consent processes alone.
The tool will utilize health information technology to deliver information about the definition of, risks, benefits, and alternatives to using increased risk donor kidneys via a web-based application.
Computer adaptive learning will personalize information presented to each candidate according to his/her comprehension levels in interactive chapters to increase comprehension.
Inform Me will facilitate nurses' primary role as patient educators.
Study Type
Interventional
Enrollment (Actual)
288
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Memorial Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- English-speaking
- 21 years or older
- Kidney Transplant candidates eligible: 1) completed the first phase of transplant evaluation education, and 2) wait-listed patients expected to receive a transplant within the next 6 months, returning for re-evaluation.
Exclusion Criteria:
- No special classes of study participants, including fetuses, neonates, prisoners, institutionalized individuals, or other vulnerable populations will be included in the proposed study. Although pregnant women will be eligible for participation in the study, they are unlikely to be selected for kidney transplantation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Inform Me: web-based education tool
Intervention will receive the standard of care, the Inform Me intervention, a post-test evaluation, and 1 week recall test.
|
The purpose of Inform Me is to help kidney transplant candidates understand what kidneys from increased risk donors are and describes the risks and benefits of accepting and refusing a kidney from an increased risk donor.
Increased risk donors are donors who engaged in behaviors that increase their chances of having: Human Immunodeficiency Virus, Hepatitis B Virus , Hepatitis C Virus.
Inform Me focuses only on increased risk donor kidneys.
Inform Me aims to prepare patients to make a decision with their transplant team to accept or to refuse a kidney from an increased risk donor.
Inform Me does not try to convince patients to accept or refuse a kidney from increased risk donors.
|
No Intervention: Control Standard of Care
This group receives standard of care with a post test.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Knowledge of increased risk donor kidney transplants
Time Frame: 1 week
|
Assess knowledge of increased risk donor kidneys
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Willingness to accept an increased risk donor kidney transplant
Time Frame: 1 week
|
Willingness to accept an increased risk donor kidney.
|
1 week
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decisional conflict
Time Frame: 1 week
|
Will measure difficulty in treatment decision-making.
|
1 week
|
Satisfaction with the informed consent process
Time Frame: 1 week
|
Assess decision-making quality, decision satisfaction, and perception of information.
|
1 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Elisa Gordon, PhD, MPH, Northwestern University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2013
Primary Completion (Actual)
December 1, 2014
Study Completion (Actual)
November 1, 2015
Study Registration Dates
First Submitted
May 20, 2013
First Submitted That Met QC Criteria
May 20, 2013
First Posted (Estimate)
May 22, 2013
Study Record Updates
Last Update Posted (Estimate)
November 20, 2015
Last Update Submitted That Met QC Criteria
November 18, 2015
Last Verified
November 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU00055356
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End-stage Kidney Disease
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
University of MichiganTheravance BiopharmaCompletedEnd-Stage Renal Disease | Stage 5 Chronic Kidney DiseaseUnited States
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of PittsburghNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedEnd-stage Kidney DiseaseUnited States
-
Ewha Womans UniversityUnknownEnd-Stage Kidney Disease
-
University of ChicagoCompletedEnd-Stage Kidney DiseaseUnited States
-
Sahlgrenska University Hospital, SwedenNot yet recruiting
-
Duke-NUS Graduate Medical SchoolNational University Hospital, Singapore; Singapore General HospitalRecruitingEnd-Stage Kidney DiseaseSingapore
-
University of WashingtonCompleted
-
AbbottTerminatedEnd-Stage Kidney DiseaseUnited States
Clinical Trials on Inform Me: web-based education tool
-
H. Lee Moffitt Cancer Center and Research InstituteRecruitingReproductive BehaviorUnited States
-
Bournemouth UniversityPoole Hospital NHS Foundation TrustCompletedAdvanced Pancreatic CancerUnited Kingdom
-
Mackay Medical CollegeTaipei Veterans General Hospital, TaiwanCompletedBreast Neoplasm Female | Fertility PreservationTaiwan
-
University of PittsburghCompletedUsability | Acceptability | Intervention ComplianceUnited States
-
Weill Medical College of Cornell UniversityCompletedBreast Cancer | Gynecologic Cancer | BRCA1 Mutation | BRCA2 MutationUnited States
-
Mackay Medical CollegeTaipei Veterans General Hospital, TaiwanCompletedBreast Neoplasm Female
-
Inonu UniversityCompletedEducation | NursingTurkey
-
KTO Karatay UniversityRecruiting
-
KTO Karatay UniversityEnrolling by invitationCOPD | Noninvasive VentilationTurkey
-
Siirt UniversityInonu UniversityCompletedDisability Physical | Genital InfectionTurkey